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support the cost-effective use of NHS resources, but other factors regularly influ-
ence decision-making.
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ASSESSING THE QUALITY OF MANUFACTURERS’ SEARCHES IN NICE SINGLE
TECHNOLOGY APPRAISALS BY EVIDENCE REVIEW GROUPS
Wong R, Paisley S, Carroll C
The University of Sheffield, Sheffield, UK
OBJECTIVES: No guidelines exist in the approach that Evidence Review Groups
(ERGs) should take to appraise search methodologies in the manufacturer’s sub-
mission (MS) in single technology appraisals (STA). As a result, ERGs are left to
appraise searches using their own approach. This study investigates the limita-
tions of manufacturers’ search methodologies as critiqued by ERGs in published
STA reports. METHODS: Limitations from search critiques in 83 ERG reports pub-
lished in the NIHR website between 2006 and May 2011 were extracted. The limi-
tations were grouped into themes. Comparisons were made between limitations
reported in the clinical effectiveness versus cost-effectiveness searches. RESULTS:
Over 60 different limitations were identified and sorted in seven broad themes:
missing studies, search strategy, reporting, sources, limits, filters and translation.
The search strategy theme contained the most limitations. Missing studies were
frequently found by the ERG group in the clinical effectiveness searches. The omis-
sion of searches by manufacturers for unpublished and ongoing trials was fre-
quently reported by the ERG. By contrast, failure of the manufacturer to report
strategies was the most common limitation in the cost-effectiveness searches
which may explain the number of missing critiques in some ERG reports. Themes
with the most frequent limitations in both types of searches are search strategy,
reporting and source. CONCLUSIONS: Variations exist in the limitations reported
in both clinical and cost-effectiveness evidence searches in STAs. It is recom-
mended that separate checklists or one that incorporates both reporting and
search strategy appraisal be used to ensure that ERG groups and manufacturers are
aware of the range of limitations that might exist when appraising searches.
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PAYER INFORMATION REQUIREMENTS FOR RELATIVE EFFECTIVENESS
ASSESSMENT VARY ACROSS MARKETS AND CREATE DISCREPENCIES IN
PATIENT ACCESS TO MEDICINES
Marinoni G1, Lockwood C1, Honoré AC1, Rodrigues T1, Izmirlieva M1, Walker S1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK
OBJECTIVES: To 1) evaluate how relative effectiveness assessment (REA) is used
within the national pricing and reimbursement (P&R) processes in 8 developed and
emerging markets; 2) to understand payer REA requirements and preferences in
each of the markets studied; and 3) to analyse how the process impacts patient
access to medicines across geographies. METHODS: IHS studied national P&R pro-
cesses through primary and secondary research to establish how REA is leveraged
to rationalise reimbursement and control price levels. Over 30 key relative effec-
tiveness assessors and P&R decision makers were interviewed to understand the
level and type of relative effectiveness evidence they look for in practice, broken
down by public versus private sector, primary versus secondary-care segment, and
key therapeutic areas. This research was further supported by real-life REA case
studies across key therapeutic areas. RESULTS: The evaluation of the therapeutic
value of a medicine can result in P&R decision discrepancies across markets. These
coverage disparities notably reflect societal and methodological differences in the
way the available evidence is interpreted across markets. In terms of how thera-
peutic value is factored into P&R decisions, markets can be segmented into two
broad categories: 1) those that rely on economic evaluation to assess therapeutic
value, and 2) those that evaluate the added therapeutic value/improvement in
actual clinical benefit without considering associated costs. In terms of informa-
tion needs, payers wish to be in a position to evaluate how new medicines compare
with the standard of care in their specific health care setting and in their patient
population when making their P&R decisions. CONCLUSIONS: REA will increas-
ingly be used in future to rationalise finite health care resources and budgets. For
now there are two schools when it comes to the methodology and patient access to
medicines is more stringent in countries that undertake economic evaluation.
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EXPLORING THE ROLE OF THE COMMITTEE IN THE NICE APPRAISAL PROCESS:
HOW CONSISTENT ARE DECISIONS ACROSS COMMITTEES?
McCann E, Plested M
HERON, Luton, UK
OBJECTIVES: NICE technology appraisals are reviewed by one of four committees
(A to D). Given the standard submission template, the information submitted as
part of the appraisal process is the same across submissions. Therefore, commit-
tees may be expected to make similar decisions regarding the acceptance or rejec-
tion of submissions. This research explored whether there were differences in
acceptances or rejections between committees and which factors affected those
decisions. METHODS: Final appraisal determinations (FADs) from October 2009 to
May 2012 were identified and reviewed. The committee, decision, and reasons for
the decision were extracted from the FADs. Rates of acceptance or rejection were
compared across the four committees using Fisher’s exact test. The composition of
each committee and the considered therapy area were also assessed. RESULTS:
This research considered 53 submissions, from which 63 recommendations were
generated. Committee A made the highest proportion of positive recommenda-
tions (75%) and Committee D made the lowest proportion (50%). The background of
committee members was similar between Committees A and B, and between C and
D, but differed between those two sets. However, the number of acceptances or
rejections did not differ significantly by committee (p0.560). Limitations in clini-
cal evidence were cited as a reason for rejection more frequently than limitations
in economic evidence across all committees. The considered therapy areas differed
between committees though cancer was the most commonly-appraised area;
Committee C reviewed the highest proportion of cancer submissions. For this ther-
apy area, the rate of acceptance or rejection did not differ significantly by commit-
tee (p0.126). CONCLUSIONS: The likelihood of positive or negative recommenda-
tions did not appear to vary by the committee assessing the submission. Given the
reasons for negative recommendations and the proportion of academic committee
members, maximising the quality and rigour of submitted evidence is a rational
approach to the appraisal process.
PHP167
THE ROLE OF DECISION-ANALYTIC MODELING IN GERMAN HEALTH
TECHNOLOGY ASSESSMENTS
Kuhlmann A1, Braun S2, Schulenburg JM1
1Leibniz Universität Hannover, Hannover, Germany, 2HERESCON GmbH, Hannover, Germany
OBJECTIVES: Decision-analytic modeling has become a widespread method ap-
plied in Health Technology Assessments (HTA), but the extent to which modeling
is used differs widely among international HTA institutions. The German Agency
for Health Technology Assessment (DAHTA) states in its methodological guidelines
that model calculations can be carried out if necessary and feasible. However,
DAHTA does not provide any methodological guidance in this regard. Aim of this
study is to quantify the current role of decision-analytic modeling in DAHTA-re-
ports and to analyze the applied methods. METHODS: All 140 DAHTA-reports pub-
lished between 1998 and May 2011 were screened for the specific development of
new decision-analytic models. To assess the impact of these models on recom-
mendations, all relevant reports were reviewed with respect to the health eco-
nomic conclusion, modeling methods and further research needs. RESULTS: A
total of 90 DAHTA-reports incorporate an economic assessment. Of these, ten re-
ports develop a new specific decision-analytic model. About 30% of the reports
without a model come to a general economic conclusion but only one report gives
a clear recommendation without major limitations. About 20% of these reports
explicitly state that the development of a model for the German setting may have
helped to come to a clear conclusion. In contrast, all reports incorporating a model
give an economic recommendation – two of these with limitations. The identified
models differ with respect to the type of health economic evaluation (cost-effec-
tiveness, cost-utility), model type (decision tree, Markov model, Monte Carlo sim-
ulation), time horizon (two weeks – life long), discount rate (3%, 5%), perspective
(statutory health insurance, care provider, social), outcome parameters (generic,
disease specific) and sensitivity analyses (one-way, multi-way, probabilistic).
CONCLUSIONS: Incorporating decision-analytic models in German HTAs has the
potential to increase the number of health economic recommendations, but only a
fraction of reports developed a specific model so far.
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CALCULATED FORECAST FOR TECHNICAL OBSOLESCENCE IN COMPUTERISED
TOMOGRAPHY EQUIPMENT
Reyes-Santias F1, Vivas-Consuelo D2, Ramos M2
1Universidad de Vigo, Vigo, Spain, 2Universidad Politecnica de Valencia, Valencia, Spain
OBJECTIVES: To estimate the useful life of Computerised Tomography Equipment
(CT) METHODS: A main components analysis in this methodology has allowed for
a reduction in the number of variables on the survey-file in Computerised Tomog-
raphy technology and facilitates subsequent work without a significant loss of
information. The Log Binomial Regression Model has enabled probability calcula-
tions on answers (technology leap) to the different levels of stimuli (changes in
variables, temporary development, detection system, imaging resolution and
equipment power). Using a Discriminant analysis, the objective has been to esti-
mate, based on time, the chances of a technological leap occurring. RESULTS: The
18 evaluated technical parameters in Computerised Tomography Technology have
been grouped in three main components: Detection System which explains 72.4% of
the variance; Imaging Resolution which explaining 13.55% of the variance and Equip-
ment Power explaining 7.1% of the variance. Logistic regression allows us to approx-
imate the influence of each main component with the passing of time, the imple-
mentation of a technology leap, with its significant influence with positive signs of
temporary evolution (0.430), and with a negative sign for the main component the
detection system(3.974), image resolution (3.766) and equipment power
(2.460). For Determinant analysis, the explanatory variables used in the model are
the 3 components calculated. The prediction model obtains a lower percentage of
success than the Log Binomial, around 66.7%. The most important factor in influ-
encing the change of technology seems to be the image resolution followed by the
detection system and a negative sing for temporary evolution. CONCLUSIONS: The
results of the present project will enable advance knowledge of the expectations of
technological change in CT technology, allowing an advance in investment plan-
ning for this technology, for acquiring and installing this type of technology.
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COMPARING THE HUNGARIAN METHODOLOGICAL GUIDELINE FOR
CONDUCTING ECONOMIC EVALUATION OF HEALTH CARE INTERVENTION
WITH EUROPEAN GUIDELINES
Huszti Z, Nagy BZ
National Institute for Quality- and Organizational Development in Healthcare and Medicines,
Budapest, Hungary
OBJECTIVES: The Hungarian methodological guideline for conducting economic
evaluation of health care interventions was published in 2002 and the modified
version will be shortly published. The 10thanniversary of the Hungarian HTA
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